Alzheon

Alzheon is a clinical-stage biotechnology company focused on women's brain health, memory, and aging, developing transformative treatments for Alzheimer's disease and other neurodegenerative disorders. They are building a portfolio of innovative drugs to improve patients' lives by preventing associated cognitive and functional decline. Alzheon’s ALZ-801 is currently the only oral anti-amyloid disease-modifying therapy in Phase 3 testing for Alzheimer’s disease. We believe ALZ-801 has the potential to significantly slow or halt disease progression and even prevent the onset of clinical symptoms.